FinscoFinsco

Ginkgo Bioworks (US.DNA)

Capital Allocation Audit · Period: 2019 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.DNA · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion105.0%→
ROE-30.8%↓
Cash Conversion-→
D/E Ratio0.96↓
Gross Margin87.8%→
US.DNA (Ginkgo Bioworks) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion   105.0%    →
ROE              -30.8%    ↓
Cash Conversion       -    →
D/E Ratio          0.96    ↓
Gross Margin      87.8%    →
Key Metrics
US.DNA (Ginkgo Bioworks) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 105.0% →
ROE -30.8% ↓
Cash Conversion - →
D/E Ratio 0.96 ↓
Gross Margin 87.8% →

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies